Otros idiomas Guard Therapeutics International AB

Acciones

GUARD

SE0021181559

Mercado cerrado - Nasdaq Stockholm Otros sitios de cotización 17:24:44 03/05/2024			Varia. Cinco días.	Varia. 1 de enero.
30 ^SEK	0,00 %		+0,67 %	-16,20 %

21/02	Guard Therapeutics International AB (publ) presenta los resultados del cuarto trimestre finalizado el 31 de diciembre de 2023	CI
21/02	Guard Therapeutics International AB (publ) informa de los resultados de ganancias para el año completo finalizado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Guard Therapeutics receives its first regulatory approval for the phase 2b study POINTER	15/04
Guard Therapeutics Receives First Regulatory Approval for the Phase 2b Study POINTER	15/04
Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/02
Guard Therapeutics International AB Reports Earnings Results for the Full Year Ended December 31, 2023	21/02
Guard Therapeutics presented development strategy and new preclinical results at R&D Update	31/01
Guard Therapeutics Presents Development Strategy and New Preclinical Results at R&D Update	31/01
Invitation to Guard Therapeutics’ R&D Update on January 30	18/01
US FDA Gives Positive Feedback on Guard Therapeutics’ RMC-035 Development Plan; Stock Plunges	15/01
FDA provides positive feedback to Guard Therapeutics regarding the continued development plan for RMC-035	15/01
Guard Therapeutics International AB Announces Fda Provides Positive Feedback to Guard Therapeutics Regarding the Continued Development Plan for RMC-035	15/01
Guard Therapeutics presents the Nomination Committee for 2024	07/12
Guard Therapeutics International AB Appoints Nomination Committee for 2024	07/12
Guard Therapeutics International AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Guard Therapeutics presents late breaking clinical trial abstract at ASN Kidney Week 2023	23/10/23
Guard Therapeutics provides more information on the development strategy for RMC-035	28/09/23
Guard Therapeutics International AB Provides More Information on the Development Strategy for RMC-035	28/09/23
Guard Therapeutics reports robust efficacy of RMC-035 in Phase 2 (AKITA) and advances clinical development program	19/09/23
Guard Therapeutics Reports Robust Efficacy of RMC-035 in Phase 2 and Advances Clinical Development Program	19/09/23
Guard Therapeutics International AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/08/23
Last patient visit completed in Guard Therapeutics' clinical Phase 2 study AKITA	14/07/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Guard Therapeutics International AB

Acciones

GUARD

SE0021181559

Otros idiomas

Filtros